+91-22-48913909UTI Healthcare Fund Vs SBI Healthcare Opportunities Fund
UTI Healthcare Fund and SBI Healthcare Opportunities Fundis a comparative article that eases the option or process of choosing one fund of the same category for the investors. Both the funds belong to the same category of Mutual Funds- healthcare sector equity. sector funds are a type of mutual fund that invests in securities of specific sectors of the Economy, such as telecom, banking, FMCG, Information Technology (IT), healthcare pharmaceutical and infrastructure. Sector funds carry a higher Volatility than any other Equity Funds. As, high-risk comes with high-reward, sector funds seem to comply with it. So, let us understand the differences between UTI Healthcare Fund and SBI Healthcare Opportunities Fund by comparing various parameters such as AUM, NAV, performance, and so on.
UTI Healthcare Fund (Erstwhile UTI Pharma & Healthcare Fund)
UTI Healthcare Fund, earlier known as UTI Pharma & Healthcare Fund, was launched in the year 1999. The aim of the fund is to seek Capital appreciation through investments in equities and related instruments of the Pharma & Healthcare sectors. Being a sector-specific fund, UTI Healthcare Fund comes under high-risk investment, thus, investors who can bear risk should only prefer Investing in this fund.
Some of the top holdings of the fund (as on 31st Jul'18) are Sun Pharmaceuticals Industries Ltd, Cipla Ltd, Torrent Pharmaceuticals Ltd, Pfizer Ltd, Sanofi India Ltd, Ipca Laboratories Ltd, etc.
SBI Healthcare Opportunities Fund (Erstwhile SBI Pharma Fund)
SBI Healthcare Opportunities Fund, earlier known as SBI Pharma Fund, was launched in the year 2004. The fund aims to provide maximum growth opportunity by investing in equity investments in stocks of growth-oriented sectors of the economy. This fund carries high-risk, so investors with the same risk appetite should only prefer investing in this fund.
Some of the top holdings of the fund, as on 31st July 2018, are Cblo, Sun Pharmaceuticals Industries Ltd, Strides Pharma Science Ltd, Aurobindo Pharma Ltd, Torrent Pharmaceuticals Ltd, etc.
UTI Healthcare Fund Vs SBI Healthcare Opportunities Fund
Basics Section
Being the first section, it compares parameters such as current NAV, Fincash Rating, AUM, expense ratio, scheme category and many more. With respect to scheme category, both the schemes are a part of the same category, Sector Equity.
Based on Fincash Rating, it can be said that, UTI Healthcare Fund is rated as 1-Star scheme and SBI Healthcare Opportunities Fund is rated as 2-Star scheme.
The comparison of the basics section is as follows.
Parameters Basics NAV Net Assets (Cr) Launch Date Rating Category Sub Cat. Category Rank Risk Expense Ratio Sharpe Ratio Information Ratio Alpha Ratio Benchmark Exit Load UTI Healthcare Fund
Growth
Fund Details ₹290.848 ↓ -1.53 (-0.52 %) ₹1,119 on 31 Aug 25 28 Jun 99 ☆ Equity Sectoral 40 High 2.26 -0.15 0.1 0.79 Not Available 0-1 Years (1%),1 Years and above(NIL) SBI Healthcare Opportunities Fund
Growth
Fund Details ₹434.577 ↓ -2.70 (-0.62 %) ₹3,963 on 31 Aug 25 31 Dec 04 ☆☆ Equity Sectoral 34 High 1.97 -0.05 0.38 2.04 Not Available 0-15 Days (0.5%),15 Days and above(NIL)
Performance Section
Being the second section, it analyses the differences in the Compounded Annual Growth Rate or CAGR returns of both the schemes. These CAGR returns are compared at different time intervals such as 1 Month Return, 6 Month Return, 5 Year Return, and Return since Inception. The comparison of CAGR returns reveals that in some instance UTI Healthcare Fund has performed better, while in some SBI Healthcare Opportunities Fund has performed well. The table given below summarizes the comparison of the performance section.
Parameters Performance 1 Month 3 Month 6 Month 1 Year 3 Year 5 Year Since launch UTI Healthcare Fund
Growth
Fund Details 2.3% -2% 7.7% 2% 23.8% 18% 14.9% SBI Healthcare Opportunities Fund
Growth
Fund Details 4.1% -1.6% 4.1% 4.7% 25.3% 20.2% 15.4%
Talk to our investment specialist
Yearly Performance Section
The comparison of absolute returns generated by both the schemes for a particular year is done in the yearly performance section. The analysis of absolute returns shows that in most years SBI Healthcare Opportunities Fund has performed well. The summary comparison of the yearly performance section is tabulated as follows.
Parameters Yearly Performance 2024 2023 2022 2021 2020 UTI Healthcare Fund
Growth
Fund Details 42.9% 38.2% -12.3% 19.1% 67.4% SBI Healthcare Opportunities Fund
Growth
Fund Details 42.2% 38.2% -6% 20.1% 65.8%
Other Details Section
The minimum SIP Investment and minimum lumpsum investment are some of the parameters that form part of the other details section. The minimum lumpsum and SIP investment for both the schemes is the same, i.e., INR 5000 and INR 500, respectively. The table given below summarizes the comparison of other details section.
SBI Healthcare Opportunities Fund is currently managed by Tanmaya Desai.
UTI Healthcare Fund is currently managed by V Srivatsa.
Parameters Other Details Min SIP Investment Min Investment Fund Manager UTI Healthcare Fund
Growth
Fund Details ₹500 ₹5,000 Kamal Gada - 3.42 Yr. SBI Healthcare Opportunities Fund
Growth
Fund Details ₹500 ₹5,000 Tanmaya Desai - 14.35 Yr.
Growth of 10k Investments over the years
UTI Healthcare Fund
Growth
Fund Details Growth of 10,000 investment over the years.
Date Value 31 Oct 20 ₹10,000 31 Oct 21 ₹12,799 31 Oct 22 ₹12,052 31 Oct 23 ₹14,059 31 Oct 24 ₹22,392 31 Oct 25 ₹22,840 SBI Healthcare Opportunities Fund
Growth
Fund Details Growth of 10,000 investment over the years.
Date Value 31 Oct 20 ₹10,000 31 Oct 21 ₹12,709 31 Oct 22 ₹12,920 31 Oct 23 ₹15,414 31 Oct 24 ₹24,279 31 Oct 25 ₹24,895
Detailed Portfolio Comparison
UTI Healthcare Fund
Growth
Fund Details Asset Allocation
Asset Class Value Cash 1.02% Equity 98.98% Equity Sector Allocation
Sector Value Health Care 97.9% Basic Materials 1.07% Top Securities Holdings / Portfolio
Name Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 06 | SUNPHARMA10% ₹105 Cr 661,016 Ajanta Pharma Ltd (Healthcare)
Equity, Since 31 Jul 17 | 5323315% ₹60 Cr 250,000
↑ 7,327 Cipla Ltd (Healthcare)
Equity, Since 31 Jan 03 | 5000875% ₹60 Cr 400,000 Lupin Ltd (Healthcare)
Equity, Since 28 Feb 25 | 5002575% ₹52 Cr 270,000 Procter & Gamble Health Ltd (Healthcare)
Equity, Since 31 Dec 20 | PGHL4% ₹44 Cr 69,320
↓ -719 Glenmark Pharmaceuticals Ltd (Healthcare)
Equity, Since 31 Mar 24 | 5322964% ₹41 Cr 210,000
↓ -10,000 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 28 Feb 18 | 5001244% ₹41 Cr 335,000
↓ -25,000 Gland Pharma Ltd (Healthcare)
Equity, Since 30 Nov 20 | GLAND4% ₹40 Cr 199,297 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Apr 21 | APOLLOHOSP4% ₹39 Cr 53,000 Alkem Laboratories Ltd (Healthcare)
Equity, Since 31 May 21 | ALKEM4% ₹39 Cr 72,000 SBI Healthcare Opportunities Fund
Growth
Fund Details Asset Allocation
Asset Class Value Cash 3.64% Equity 96.36% Equity Sector Allocation
Sector Value Health Care 90.67% Basic Materials 5.69% Top Securities Holdings / Portfolio
Name Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Dec 17 | SUNPHARMA11% ₹430 Cr 2,700,000 Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB6% ₹250 Cr 440,000 Max Healthcare Institute Ltd Ordinary Shares (Healthcare)
Equity, Since 31 Mar 21 | MAXHEALTH6% ₹223 Cr 2,000,000
↓ -100,000 Cipla Ltd (Healthcare)
Equity, Since 31 Aug 16 | 5000875% ₹180 Cr 1,200,000 Lupin Ltd (Healthcare)
Equity, Since 31 Aug 23 | 5002574% ₹161 Cr 840,000 Lonza Group Ltd ADR (Healthcare)
Equity, Since 31 Jan 24 | LZAGY4% ₹160 Cr 270,000 Fortis Healthcare Ltd (Healthcare)
Equity, Since 30 Apr 21 | 5328434% ₹145 Cr 1,500,000 Torrent Pharmaceuticals Ltd (Healthcare)
Equity, Since 30 Jun 21 | TORNTPHARM4% ₹144 Cr 400,000 Gland Pharma Ltd (Healthcare)
Equity, Since 30 Nov 20 | GLAND4% ₹139 Cr 700,000 Mankind Pharma Ltd (Healthcare)
Equity, Since 30 Apr 23 | MANKIND3% ₹132 Cr 540,000
↓ -20,000
Therefore, in a nutshell, it can be said that both the schemes differ on account of numerous parameters. As a consequence, individuals should be very careful while choosing any of the schemes for investment. They should understand the modalities of the scheme completely and check whether the scheme matches their investment parameters or not. This will help individuals to attain their objectives on time and in a hassle-free manner.
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data. Please verify with scheme information document before making any investment.
AMFI Registration No. 112358 | CIN: U74999MH2016PTC282153
Shepard Technologies Pvt. Ltd. (with ARN code 112358) makes no warranties or representations, express or implied, on products offered through the platform. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Terms and conditions of the website are applicable.
©2025 Shepard Technologies Private Limited. All Rights Reserved